Pregnancy as a cardiac stress model

Cardiovascular Research

Volumn 101, Issue 4, 2014, Pages 561-570

  Chung, Eunhee ^a   Leinwand, Leslie A ^b  

^a TEXAS TECH UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Hormones; Molecular signatures; Physiological cardiac hypertrophy; Pregnancy; Signalling pathways

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CALCINEURIN; COLLAGEN TYPE 1; ELASTIN; ESTRADIOL; GELATINASE A; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROTEIN KINASE B; RELAXIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; CAPILLARY DENSITY; CARDIOVASCULAR RESPONSE; CONGESTIVE CARDIOMYOPATHY; CYTOKINE RELEASE; DIASTOLIC DYSFUNCTION; ENDURANCE TRAINING; EXERCISE; GENE EXPRESSION; GENE INDUCTION; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART STRESS; HEART STROKE VOLUME; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; HORMONE ACTION; HUMAN; MATERNAL MORTALITY; MODEL; MORPHOLOGICAL ADAPTATION; NONHUMAN; PERIPARTUM CARDIOMYOPATHY; PHENOTYPE; PHYSIOLOGICAL STRESS; PREGNANCY; PRIORITY JOURNAL; REVIEW; SECOND TRIMESTER PREGNANCY; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; THIRD TRIMESTER PREGNANCY; VASCULAR RESISTANCE; ANIMAL; FEMALE; HEART; HEART DISEASES; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY COMPLICATION;

ANIMALS; EXERCISE; FEMALE; HEART; HEART DISEASES; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84905511823     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu013     Document Type: Review

References (100)

1. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589-600.
2. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007;34:255-262.
3. Gonzalez AMD, Osorio JC, Manlhiot C, Gruber D, Homma S, Mital S. Hypertrophy signaling during peripartum cardiac remodeling. Am J Physiol Heart Circ Physiol 2007;293:H3008-H3013.
4. Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol 2010;300:H931-H942.
5. Iorga A, Dewey S, Partow-Navid R, Gomes AV, Eghbali M. Pregnancy is associated with decreased cardiac proteasome activity and oxidative stress in mice. PLoS One 2012;7:e48601.
6. Chung E, Yeung F, Leinwand LA. Akt and MAPK signaling mediate pregnancy-induced cardiac adaptation. J Appl Physiol 2012;112:1565-1575.
7. Frenzel H, Schwartzkopff B, Höltermann W, Schnürch HG, Novi A, Hort W. Regression of cardiac hypertrophy: morphometric and biochemical studies in rat heart after swimming training. J Mol Cell Cardiol 1988;20:737-751.
8. Eghbali M, Wang Y, Toro L, Stefani E. Heart hypertrophy during pregnancy: a better functioning heart? Trends Cardiovasc Med 2006;16:285-291.
9. Hainsey T, Csiszar A, Sun S, Edwards JG. Cyclosporin A does not block exercise-induced cardiac hypertrophy. Med Sci Sports Exerc 2002;34:1249-1254.
10. Eghbali M, Deva R, Alioua A, Minosyan TY, Ruan H, Wang Y et al. Molecular and functional signature of heart hypertrophy during pregnancy. Circ Res 2005;96:1208-1216.
11. Chung E, Heimiller J, Leinwand LA. Distinct cardiac transcriptional profiles defining pregnancy and exercise. PLoS One 2012;7:e42297.
12. Dorn GW II. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007;49:962-970.
13. Bassien-Capsa V, Fouron J-C, Comte B, Chorvatova A. Structural, functional and metabolic remodeling of rat left ventricular myocytes in normal and in sodiumsupplemented pregnancy. Cardiovasc Res 2006;69:423-431.
14. Maillet M, Van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol 2013;14:38-48.
15. Hunter JJ, Chien KR. Mechanismsofdisease: signalingpathways for cardiac hypertrophy and failure. N Engl J Med 1999;341:1276-1283.
16. Perrino C, Prasad SVN, Mao L, Noma T, Yan Z, Kim H-S et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 2006;116:1547-1560.
17. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB. Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998;98:656-662.
18. Shapiro LM. Physiological left ventricular hypertrophy. Br Heart J 1984;52:130-135.
19. Umar S, Nadadur R, Iorga A, Amjedi M, Matori H, Eghbali M. Cardiac structural and hemodynamic changes associated with physiological heart hypertrophy of pregnancy are reversed postpartum. J Appl Physiol 2012;113:1253-1259.
20. Robson SC, Hunter S, Moore M, Dunlop W. Haemodynamic changes during the puerperium: a Doppler and M-mode echocardiographic study. Br J Obset Gynaecol 1987;94:1028-1039.
21. Clapp JF, Capeless E. Cardiovascular function before, during, and after the first and subsequent pregnancies. Am J Cardiol 1997;80:1469-1473.
22. Bond CF. Blood volume changes in the lactating rat. Endocrinology 1958;63:285-289.
23. Longo LD. Maternal blood volume and cardiac output during pregnancy: a hypothesis of endocrinologic control. Am J Physiol Regul Integr Comp Physiol 1983;245:R720-R729.
24. Barron WM, Mujais SK, Zinaman M, Bravo EL, Lindheimer MD. Plasma catecholamine responses to physiologic stimuli in normal human pregnancy. Am J Obstet Gynecol 1986;154:80-84.
25. Conrad KP. Maternal vasodilationinpregnancy: the emerging roleofrelaxin. AmJ Physiol Regul Integr Comp Physiol 2011;301:R267-R275.
26. Natrajan PG, McGarrigle HH, Lawrence DW, Lachelin GC. Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension. Br J Obstet Gynaecol 1982;89:1041-1045.
27. Whittaker PG, Gerrard J, Lind T. Catecholamin responses to changes inposture during human pregnancy. Br J Obstet Gynaecol 1985;92:586-592.
28. Nisell H, Hjemdahl P, Linde B. Cardiovascular responses to circulating catecholamines in normal pregnancy and pregnancy-induced hypertension. Clin Physiol 1985;5:479-493.
29. Virgo BB, Bellward GD. Serum progesterone levels in the pregnant and postpartum laboratory mouse. Endocrinology 1974;95:1486-1490.
30. McCormack JT, Greenwald GS. Progesterone and oestradiol-17b concentrationsinthe peripheral plasma during pregnancy in the mouse. J Endocrinol 1974;62:101-107.
31. Murr SM, Stabenfeldt GH, Bradford GE, Geschwind II. Plasma progesterone during pregnancy in the mouse. Endocrinology 1974;94:1209-1211.
32. Goldstein J, Sites CK, Toth MJ. Progesterone stimulates cardiacmuscle protein synthesis via receptor-dependent pathway. Fert Steril 2004;82:430-436.
33. Chung E, Yeung F, Leinwand LA. Calcineurin activity is required for cardiac remodeling in pregnancy. Cardiovasc Res 2013;100:402-410.
34. Van Eickels M, Grohe C, Cleutjens JPM, Janssen BJ, Wellens HJJ, Doevendans PA. 17{beta}-estradiol attenuates the development of pressure-overload hypertrophy. Circulation 2001;104:1419-1423.
35. Hart MV, Hosenpud JD, Hohimer AR, Morton MJ. Hemodynamics during pregnancy and sex steroid administration in guinea pigs. Am J Physiol Regul Integr Comp Physiol 1985;249:R179-R185.
36. Serra AJ, Santos MHH, Bocalini DS, Antônio EL, Levy RF, Santos AA et al. Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity. J Physiol 2010;588:2431-2442.
37. Murray DR, Prabhu SD, Chandrasekar B. Chronic b-adrenergic stimulation induces myocardial pro-inflammatory cytokine expression. Circulation 2000;101:2338-2341.
38. Xia Y, Lee K, Li N, Corbett D, Mendoza L, Frangogiannis N. Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol 2009;131:471-481.
39. Iemitsu M, Maeda S, Miyauchi T, Matsuda M, Tanaka H. Gene expression profiling of exercise-induced cardiac hypertrophy in rats. Acta Physiol Scand 2005;185:259-270.
40. MacDonald C, Wojtaszewski JFP, Pedersen BK, Kiens B, Richter EA. Interleukin-6 release from human skeletal muscle during exercise: relation to AMPK activity. J Appl Physiol 2003;95:2273-2277.
41. Velez DR, Fortunato SJ, Morgan N, Edwards TL, Lombardi SJ, Williams SM et al. Patterns of cytokine profiles differ with pregnancy outcome and ethnicity. Hum Reprod 2008;23:1902-1909.
42. Pazos P, Lima L, Casanueva FF, Diéguez C, García MC. Interleukin 6 deficiency modulates the hypothalamic expression of energy balance regulating peptides during pregnancy in mice. PLoS One 2013;8:e72339.
43. Vassiliadis S, Ranella A, Papadimitriou L, Makrygiannakis A, Athanassakis I. Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion. Mediators Inflamm 1998;7:69-72.
44. Vogiagis D, Salamonsen LA. The roleof leukaemia inhibitory factorin the establishment of pregnancy. J Endocrinol 1999;160:181-190.
45. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res Cardiol 2007;102:279-297.
46. Diffee GM, Chung E. Altered single cell force-velocity and power properties in exercise-trained rat myocardium. J Appl Physiol 2003;94:1941-1948.
47. Savu O, Jurcuţ R, Giuşcə S, Van Mieghem T, Gussi I, Popescu BA et al. Morphological and functional adaptation of the maternal heart during pregnancy. Circ Cardiovasc Imag 2012;5:289-297.
48. Mone SM, Sanders SP, Colan SD. Control mechanisms for physiological hypertrophy of pregnancy. Circulation 1996;94:667-672.
49. Schannwell CM, Zimmermann T, Schneppenheim M, Plehn G, Marx R, Strauer BE. Left ventricular hypertophy and diastolic dysfunctioninhealthy pregnant women. Cardiology 2002;97:73-78.
50. Li J, Umar S, Iorga A, Youn J-Y, Wang Y, Regitz-Zagrosek V et al. Cardiac vulnerability to ischemia/reperfusion injury drastically increases in late-pregnancy. Basic Res Cardiol 2012;107:1-11.
51. Buttrick PM, Schaible TF, Malhotra A, Mattioli S, Scheuer J. Effects of pregnancy on cardiac function and myosin enzymology in the rat. Am J Physiol Heart Circ Physiol 1987;252:H846-H850.
52. Graham HK, Horn M, Trafford AW. Extracellular matrix profiles in the progression to heart failure. Acta Physiol 2008;194:3-21.
53. Souders CA, Borg TK, Banerjee I, Baudino TA. Pressure overload induces early morphological changes in the heart. Am J Pathol 2012;181:1226-1235.
54. Brower GL, Gardner JD, Forman MF, Murray DB, Voloshenyuk T, Levick SP et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006;30:604-610.
55. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: embracing the MMP-independent-side of the family. J Mol Cell Cardiol 2010;48:445-453.
56. Mori S, Gibson G, McTiernan CF. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model. J Card Fail 2006;12:314-325.
57. Marijianowski MM, Teeling P, Mann J, Becker AE. Dilated cardiomyopathy is associated with an increase in the type I/type III collagen ratio: a quantitative assessment. J Am Coll Cardiol 1995;25:1263-1272.
58. Mujumdar VS, Tyagi SC. Temporal regulation of extracellular matrix components in transition from compensatory hypertrophy to decompensatory heart failure. J Hypertens 1999;17:261-270.
59. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112:1136-1144.
60. Jin H, Yang R, Li W, Lu H, Ryan AM, Ogasawara AK et al. Effects of exercise training on cardiac function, gene expression, and apoptosis in rats. Am J Physiol Heart Circ Physiol 2000;279:H2994-H3002.
61. Aljabri MB, Songstad NT, Lund T, Serrano MC, Andreasen TV, Al-Saad S et al. Pregnancy protects against antiangiogenic and fibrogenic effectsof angiotensin II in rat hearts. Acta Physiol 2011;201:445-456.
62. Zamani P, Greenberg B. Novel vasodilators in heart failure. Curr Heart Fail Rep 2013;10:1-11.
63. Rimbaud S, Sanchez H, Garnier A, Fortin D, Bigard X, Veksler V et al. Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol 2009;46:952-959.
64. Edwards JG. Swim training increases ventricular atrial natriuretic factor (ANF) gene expression as an early adaptation to chronic exercise. Life Sci 2002;70:2753-2768.
65. Diffee GM, Seversen EA, Stein TD, Johnson JA. Microarrayexpression analysisofeffects of exercise training: increase in atrial MLC-1 in rat ventricles. Am J Physiol Heart Circ Physiol 2003;284:H830-H837.
66. Scheinowitz M, Kessler-Icekson G, Freimann S, Zimmermann R, Schaper W, Golomb E et al. Short- and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression. Growth Horm IGF Res 2003;13:19-25.
67. Stilli D, Bocchi L, Berni R, Zaniboni M, Cacciani F, Chaponnier C et al. Correlation of a-skeletal actin expression, ventricular fibrosis and heart function with the degree of pressure overload cardiac hypertrophy in rats. Exp Physiol 2006;91:571-580.
68. Carneiro-Júnior MA, Quintão-Júnior JF, Drummond LR, Lavorato VN, Drummond FR, Da Cunha DNQ et al. The benefits of endurance training in cardiomyocyte function in hypertensive rats are reversed within four weeks of detraining. J Mol Cell Cardiol 2013;57:119-128.
69. Kolwicz SC, Tian R. Glucose metabolism and cardiac hypertrophy. Cardiovasc Res 2011;90:194-201.
70. Garnier A, Fortin D, Deloménie C, Momken I, Veksler V, Ventura-Clapier R. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol 2003;551:491-501.
71. Butte NF, Hopkinson JM, Mehta N, Moon JK, Smith EOB. Adjustments in energy expenditure and substrate utilization during late-pregnancy and lactation. Am J Clin Nutr 1999;69:299-307.
72. Butte NF. Carbohydrate and lipid metabolisminpregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000;71:1256s-1261s.
73. De Bosch B, Treskov I, Lupu TS, Weinheimer C, Kovacs A, Courtois M et al. Akt1 is required for physiological cardiac growth. Circulation 2006;113:2097-2104.
74. McMullen JR, Shioi T, Zhang L, Tarnavski O, Sherwood MC, Kang PM et al. Phosphoinositide 3-kinase (p110{alpha}) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 2003;100:12355-12360.
75. Dorn GW II, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005;115:527-537.
76. Shioi T, Kang PM, Douglas PS, Hampe J, Yballe CM, Lawitts J et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J 2000;19:2537-2548.
77. Konhilas JP, Maass AH, Luckey SW, Stauffer BL, Olson EN, Leinwand LA. Sex modifies exercise and cardiac adaptation in mice. Am J Physiol Heart Circ Physiol 2004;287:H2768-H2776.
78. Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 2002;277:22896-22901.
79. Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G et al. Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 2002;99:12333-12338.
80. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of Akt signaling. J Biol Chem 2005;280:20814-20823.
81. Antos CL, McKinsey TA, Frey N, Kutschke W, McAnally J, Shelton JM et al. Activated glycogen synthase-3beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 2002;99:907-912.
82. Hilfiker-Kleiner D, Kaminski K, Podewski E, Bonda T, Schaefer A, Sliwa K et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600.
83. Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB et al.. Enhanced Galpha q signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 1998;95:10140-10145.
84. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ. Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 1998;280:574-577.
85. Iemitsu M, Maeda S, Jesmin S, Otsuki T, Kasuya Y, Miyauchi T. Activation pattern of MAPK signaling in the hearts of trained and untrained rats following a single bout of exercise. J Appl Physiol 2006;101:151-163.
86. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophyintransgenic mice. Embo J 2000;19:6341-6350.
87. Yamaguchi O, Higuchi Y, Hirotani S, Kashiwase K, Nakayama H, Hikoso S et al. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc Natl Acad Sci USA 2003;100:15883-15888.
88. Taniike M, Yamaguchi O, Tsujimoto I, Hikoso S, Takeda T, Nakai A et al. Apoptosis signal-regulating kinase 1/p38 signaling pathway negatively regulates physiological hypertrophy. Circulation 2008;117:545-552.
89. Wilkins BJ, Dai Y-S, Bueno OF, Parsons SA, Xu J, Plank DM et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 2004;94:110-118.
90. Haq S, Choukroun G, Lim H, Tymitz KM, Del Monte F, Gwathmey J et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001;103:670-677.
91. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:1690-1693.
92. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IGP, Schoen FJ et al. An abnormal Ca2+ response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 2000;106:1351-1359.
93. Eto Y, Yonekura K, Sonoda M, Arai N, Sata M, Sugiura S et al. Calcineurin is activated in rat hearts with physiological left ventricular hypertrophy induced by voluntary exercise training. Circulation 2000;101:2134-2137.
94. Konhilas JP, Widegren U, Allen DL, Paul AC, Cleary A, Leinwand LA. Loaded wheel running and muscle adaptation in the mouse. Am J Physiol Heart Circ Physiol 2005;289:H455-H465.
95. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R et al. Disruption of coordinated cardiac hypertrophyand angiogenesis contributestothe transitiontoheart failure. JClin Invest 2005;115:2108-2118.
96. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992;72:369-417.
97. Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012;485:333-338.
98. Shiojima I, Walsh K. Regulationofcardiac growth and coronaryangiogenesisbythe Akt/PKB signaling pathway. Genes Dev 2006;20:3347-3365.
99. Pelliccia A, Maron BJ, De Luca R, Di Paolo FM, Spataro A, Culasso F. Remodeling of left ventricular hypertrophy in elite athletes after long-term deconditioning. Circulation 2002;105:944-949.
100. Hilfiker-Kleiner D, Struman I, Hoch M, Podewski E, Sliwa K. 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heart Fail Rep 2012;9:174-182.